WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Download IconDownload Print IconPrint

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Firm News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Emergent BioSolutions, which offers specialized products to healthcare providers and governments to address medical needs and emerging health threats, announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal is expected to close by the end of the year.

The WilmerHale team representing Emergent BioSolutions was led by Jeffrey Hermanson and includes Belinda Juran, Sam Rothberg, Alex Civetta, Jasmine Haddad, Hartmut Schneider, Julie Hogan Rodgers and Bruce Manheim.

To learn more about the acquisition, read Emergent BioSolutions' press release.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel